Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis

被引:24
作者
Kaas, A. [1 ]
Pfleger, C. [3 ]
Hansen, L. [1 ]
Buschard, K. [2 ]
Schloot, N. C. [3 ,4 ]
Roep, B. O. [5 ]
Mortensen, H. B. [1 ]
机构
[1] Glostrup Univ Hosp, Dept Paediat, DK-2600 Glostrup, Denmark
[2] Rigshosp, Bartholin Inst, DK-2100 Copenhagen, Denmark
[3] Univ Dusseldorf, Inst Clin Diabetol, German Diabet Ctr, Leibniz Ctr Diabet Res, D-4000 Dusseldorf, Germany
[4] Univ Hosp, Dept Internal Med Metab Dis, Dusseldorf, Germany
[5] Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, Leiden, Netherlands
关键词
adiponectin; C-peptide; paediatric; residual beta cell function; type; 1; diabetes; FATTY-ACID OXIDATION; BETA-CELL FUNCTION; SERUM CONCENTRATIONS; CHEMOKINE IP-10/CXCL10; MELLITUS PATIENTS; REMISSION; CHILDREN; TOLERANCE; ALPHA; PHASE;
D O I
10.1111/j.1365-2249.2010.04193.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
P>The progression of type 1 diabetes after diagnosis is poorly understood. Our aim was to assess the relation of disease progression of juvenile-onset type 1 diabetes, determined by preserved beta cell function the first year after diagnosis, with systemic cytokine concentrations and number of autoantibodies. Juvenile patients (n = 227) had a meal-stimulated C-peptide test 1 and 6 months after diagnosis. On the basis of the C-peptide course for the duration of 1-6 months, four progression groups were defined: patients with persistently low beta cell function ('stable-low'), rapid progressers, slow progressers and remitters. Serum concentrations of adiponectin, interleukin (IL)-1ra, inducible protein 10 (IP-10), IL-6 and glutamic acid decarboxylase (GAD), IA-2A and islet-cell antibodies (ICA) were measured at 1, 6 and 12 months. We found that adiponectin concentrations at 1 month predicted disease progression at 6 months (P = 0 center dot 04). Patients with low adiponectin had a higher probability of becoming remitters than rapid progressers, odds ratio 3 center dot 1 (1 center dot 3-7 center dot 6). At 6 and 12 months, adiponectin differed significantly between the groups, with highest concentrations among stable-low and rapid progressers patients (P = 0 center dot 03 and P = 0 center dot 006). IL-1ra, IP-10 and IL-6 did not differ between the groups at any time-point. The number of autoantibodies differed significantly between the groups at 1 month (P = 0 center dot 04), where rapid progressers had the largest number. There was no difference between the groups in human leucocyte antigen-associated risk. We define progression patterns distinguishing patients diagnosed with low beta cell function from those with rapid decline, slow decline or actual increase in beta cell function, pointing to different mechanisms of disease progression. We find that adiponectin concentration at 1 month predicts, and at 6 and 12 months associates with, distinct progression patterns.
引用
收藏
页码:444 / 452
页数:9
相关论文
共 33 条
[1]   Type 1 diabetes: new perspectives on disease pathogenesis and treatment [J].
Atkinson, MA ;
Eisenbarth, GS .
LANCET, 2001, 358 (9277) :221-229
[2]   The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J].
Berg, AH ;
Combs, TP ;
Du, XL ;
Brownlee, M ;
Scherer, PE .
NATURE MEDICINE, 2001, 7 (08) :947-953
[3]   Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty [J].
Bonfanti, R ;
Bognetti, E ;
Meschi, F ;
Brunelli, A ;
Riva, MC ;
Pastore, MR ;
Calori, G ;
Chiumello, G .
ACTA DIABETOLOGICA, 1998, 35 (02) :91-95
[4]   Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase [J].
Carey, Andrew L. ;
Steinberg, Gregory R. ;
Macaulay, S. Lance ;
Thomas, Walter G. ;
Holmes, Anna G. ;
Ramm, Georg ;
Prelovsek, Oja ;
Hohnen-Behrens, Cordula ;
Watt, Matthew J. ;
James, David E. ;
Kemp, Bruce E. ;
Pedersen, Bente K. ;
Febbraio, Mark A. .
DIABETES, 2006, 55 (10) :2688-2697
[5]   Circulating adipocytokines in non-diabetic and Type 1 diabetic children: relationship to insulin therapy, glycaemic control and pubertal development [J].
Celi, F. ;
Bini, V. ;
Papi, F. ;
Santilli, E. ;
Castellani, M. S. ;
Ferretti, A. ;
Mencacci, M. ;
Berioli, M. G. ;
De Giorgi, G. ;
Falorni, A. .
DIABETIC MEDICINE, 2006, 23 (06) :660-665
[6]   Among CXCR3 chemokines, IFN-γ-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-γ (CXCL9) imprints a pattern for the subsequent development of autoimmune disease [J].
Christen, U ;
McGavern, DB ;
Luster, AD ;
von Herrath, MG ;
Oldstone, MBA .
JOURNAL OF IMMUNOLOGY, 2003, 171 (12) :6838-6845
[7]   Phases of diabetes [J].
Couper, Jennifer ;
Donaghue, Kim .
PEDIATRIC DIABETES, 2007, 8 (01) :44-47
[8]  
DCCT Res Grp, 1987, J CLIN ENDOCR METAB, V65, P30
[9]   Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications [J].
Frystyk, J ;
Tarnow, L ;
Hansen, TK ;
Parving, HH ;
Flyvbjerg, A .
DIABETOLOGIA, 2005, 48 (09) :1911-1918
[10]   Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in Type 1 Diabetes [J].
Greenbaum, Carla J. ;
Mandrup-Poulsen, Thomas ;
Friedenberg, Paula ;
Battelino, Tadej ;
Haastert, Burkhard ;
Ludvigsson, Johnny ;
Pozzilli, Paolo ;
Lachin, John M. ;
Kolb, Hubert .
DIABETES CARE, 2008, 31 (10) :1966-1971